Sundyota Numandis ties up with Germany’s Finzelberg for healthcare products

Our Bureau Ahmedabad | Updated on February 14, 2018 Published on February 14, 2018

The Sundyota Numandis Group, on Wednesday, announced a strategic alliance with Finzelberg, Germany, to offer novel, natural healthcare products in India.

To start with, Sundyota Numandis will introduce ERr731, a product complementing women’s health during menopause and pre-menopause.

Sundyota Numandis is a global health-oriented organisation focused on providing safe healthcare products and clinically proven therapies from non-synthetic sources.

Finzelberg is a business unit of the Martin Bauer Group (Germany), manufacturing phyto-pharmaceuticals and phyto-nutraceuticals. The Martin Bauer Group is a supplier of herbal and fruit infusions, medicinal teas, flavoured black and green teas, aromas, herbal powders, botanicals, herbal, fruit and tea extracts. As part of the pact, Sundyota Numandis will procure active ingredients from Finzelberg, undertake their formulation and development and seek registration and regulatory approvals for the same. This will be followed by commercial manufacturing along with product launch, marketing and co-marketing through promotion to doctors and pharmaceutical companies in India, said Dinesh Kumar Arora, Managing Director-CEO, Sundyota Numandis.

The new product, unveiled here, aims to ease over 20 symptoms related to menopause and pre-menopause, thus acting as a natural female hormone. Being devoid of any side-effects over long term use, it has a safety profile. “We now have 12 international alliances to foster healthcare the natural way along with over 60 patented therapies. ERr731 is safer than any currently available therapy for menopause. It facilitates a smooth transition for women experiencing menopause,” he said.

Published on February 14, 2018

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.